5-氯-2-氧代-3-(噻吩-2-羰基)-3H-吲哚-1-甲酰胺 | 100599-27-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 5-氯-2-氧代-3-(噻吩-2-羰基)-3H-吲哚-1-甲酰胺
• 英文名称: tenidap
• 英文别名: 5-chloro-2,3-dihydro-2-oxo-3-(thien-2-ylcarbonyl)-indole-1-carboxamide；2,3-Dihydro-5-chloro-2-oxo-3-(2-thienylcarbonyl)-1H-indole-1-carboxamide；5-chloro-2-oxo-3-(thiophene-2-carbonyl)-3H-indole-1-carboxamide
• CAS: 100599-27-7
• 化学式: C₁₄H₉ClN₂O₃S
• 分子量: 320.756
• InChiKey: IGPDWKCUDHIIRL-UHFFFAOYSA-N

物化性质

• 沸点：
  523.9±60.0 °C(Predicted)
• 密度：
  1.580±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  109
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-氯-2-氧代-3-(噻吩-2-羰基)-3H-吲哚-1-甲酰胺 生成 sodium;5-chloro-2-oxo-3-(thiophene-2-carbonyl)-3H-indole-1-carboximidate
  参考文献：
  名称：

  摘要：

  DOI：
• 作为产物：
  描述：

  5-氯氧化吲哚 在 4-二甲氨基吡啶 、 sodium acetate 、 乙酸酐 、 溶剂黄146 、 三乙胺 、 sodium hydroxide 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 9.0h， 生成 5-氯-2-氧代-3-(噻吩-2-羰基)-3H-吲哚-1-甲酰胺
  参考文献：
  名称：

  Synthesis of Tenidap: An Improved Process for the Preparation of 5-Chloro-2-oxindole-1-carboxamide

  摘要：

  An industrially viable, robust, and economic process is developed for Tenidap sodium and its important intermediate 5-chloro-2-oxindole-1-carboxamide. Use of inorganic cyanates, in place of organic isocyanates, makes the process simple and commercially viable. The advantage of using acetic anhydride and sodium acetate over reported reagents such as trifluoroacetic acid and its anhydride on industrial scale is described. Drastic reduction of DMAP in the final step and overall improvement of yields makes the process economical.

  DOI：

  10.1021/op000082b

文献信息

• PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY
  申请人：Rewcastle Gordon William

  公开号：US20110009405A1

  公开（公告）日：2011-01-13

  Provided herein are pyrimidinyl and 1,3,5-triazinyl benzimidazoles of Formula I, and their pharmaceutical compositions, preparation, and use as agents or drugs for cancer therapy, either alone or in combination with radiation and/or other anticancer drugs.

  本文提供了式I的嘧啶基和1,3,5-三嗪基苯并咪唑化合物，以及它们的药物组合物、制备方法，以及作为抗癌治疗药物或药剂的用途，可以单独使用，也可以与放疗和/或其他抗癌药物联合使用。
• [EN] METHYL OXAZOLE OREXIN RECEPTOR ANTAGONISTS<br/>[FR] MÉTHYLOXAZOLES ANTAGONISTES DU RÉCEPTEUR DE L'OREXINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2016089721A1

  公开（公告）日：2016-06-09

  The present invention is directed to methyl oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及甲基噁唑化合物，其为促进睡眠的受体拮抗剂。本发明还涉及所述化合物在潜在治疗或预防涉及促进睡眠的神经和精神疾病和疾病中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在预防或治疗涉及促进睡眠的疾病中的用途。
• 3-Aminocyclopentanecarboxamides as modulators of chemokine receptors
  申请人：Xue Chu-Biao

  公开号：US20060004018A1

  公开（公告）日：2006-01-05

  The present invention is directed to compounds of Formula I: which are modulators of chemokine receptors. The compounds of the invention, and compositions thereof, are useful in the treatment of diseases related to chemokine receptor expression and/or activity.

  本发明涉及以下式的化合物： 这些化合物是趋化因子受体的调节剂。本发明的化合物及其组合物在治疗与趋化因子受体表达和/或活性相关的疾病方面是有用的。
• [EN] SUBSTITUTED HETEROCYCLES AS BROMODOMAIN INHIBITORS<br/>[FR] HÉTÉROCYCLES SUBSTITUÉS À TITRE D'INHIBITEURS DE BROMODOMAINES
  申请人：ZENITH EPIGENETICS CORP

  公开号：WO2016092375A1

  公开（公告）日：2016-06-16

  The present application relates to substituted heterocycles compound of Formula I and pharmaceutical compositions thereof useful for the inhibition of BET protein function by binding to bromodomains (Formula I).

  本申请涉及Formula I的取代杂环化合物及其制药组合物，用于通过结合溴结构域（Formula I）抑制BET蛋白功能。
• Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors
  申请人：Goble D. Stephen

  公开号：US20070238723A1

  公开（公告）日：2007-10-11

  Cyclopentyl compounds linked to a benzoxazinyl group through an amido moiety utilizing the ring nitrogen of the benzoxazine, and further substituted with a heterocyclic moiety, such compounds represented by formula I: which are used to modulate the CCR-2 chemokine receptor to prevent or treat inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis; and pharmaceutical compositions comprising these compounds and the use of these compounds and compositions.

  环戊基化合物通过酰胺基团与苯并噁唑基团相连，利用苯并噁唑环的环氮原子，并进一步用杂环基团取代，这些化合物由式I表示： 用于调节CCR-2趋化因子受体，以预防或治疗炎症和免疫调节性疾病和疾病，过敏性疾病，包括过敏性鼻炎，皮炎，结膜炎和哮喘，以及类风湿性关节炎和动脉粥样硬化等自身免疫病理病变；以及包含这些化合物的药物组合物和这些化合物和组合物的使用。